Abstract
Beneficial effects of bone-acting drugs in osteoarthritis (OA) are increasingly reported, but reliable conclusions regarding their efficacy are hindered by methodological drawbacks in study design. Identifying patients with osteoporotic OA, a phenotype defined by decreased density associated with high remodelling in subchondral bone, might improve the success of bone-directed agents.
Publication types
-
News
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Bone Density Conservation Agents / pharmacology
-
Bone Density Conservation Agents / therapeutic use*
-
Bone Remodeling / drug effects
-
Diphosphonates / pharmacology
-
Diphosphonates / therapeutic use*
-
Humans
-
Osteoarthritis, Knee / drug therapy*
-
Osteoporosis / drug therapy*
Substances
-
Bone Density Conservation Agents
-
Diphosphonates